Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Breast 2Thoracic 1Head & Neck 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 4Recurrence 3Esophageal Squamous Cell Carcinoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Melanoma 2Leukemia, Myeloid, Acute 2Endometrial Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Barrett Esophagus 2Adenocarcinoma Of Esophagus 2Tuberous Sclerosis 1Solid Tumors 1Refractory or Relapsed Solid Tumors 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma, Follicular 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

pembrolizumab 96Carboplatin 67Paclitaxel 56Cyclophosphamide 40Capecitabine 30Specimen Handling 28sacituzumab govitecan 25130-nm albumin-bound paclitaxel 24Gemcitabine 22Magnetic Resonance Spectroscopy 21Doxorubicin 20olaparib 19Taxes 19Biopsy 19Albumin-Bound Paclitaxel 19Drug Therapy 16atezolizumab 13Nivolumab 13toripalimab 12Radiotherapy 12Epirubicin 12durvalumab 11Docetaxel 10Cisplatin 10Bevacizumab 10eribulin 9fludarabine 8Standard of Care 7Radiation 7Injections 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Itraconazole × 1 year × Clear all
NCT06084481 2026-01-20

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

AbbVie

Phase 1 Active not recruiting
302 enrolled
BreastGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Triple Negative Breast Neoplasms

NCT06400472 2026-01-14

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Recruiting
495 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡